ReviewAnti-cancer agents in medicinal chemistry2013
Role of calcium, vitamin D, and the extrarenal vitamin D hydroxylases in carcinogenesis.
Review in Anti-cancer agents in medicinal chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- The Impact of Vitamin D Deficiency and Insufficiency on the Outcome of Type 2 Diabetes Mellitus Patients: A Systematic Review.Nutrients · 2023Pooled it
- Trial
- The Redox Paradox of Natural Supplements in Cancer: A Narrative Review to Guide Clinical Practice.Antioxidants (Basel, Switzerland) · 2026Review
- The Link BetweenBioMed research international · 2026Article
- Vitamin D-induced mechanisms in cancer prevention and therapy: Recent advances and future opportunities.Animal models and experimental medicine · 2025Review
- Ectopic production of 1,25-dihydroxyvitamin D in high-grade intranasal non-intestinal-type adenocarcinoma induced hypercalcemic crisis: a case report with review of literature.Endocrine journal · 2025Review
- Therapeutic implications of vitamin D in leukemia: mechanistic and clinical perspectives.Medical oncology (Northwood, London, England) · 2025Review
- Serum 25(OH)D levels and mortality risk among middle-aged and elderly populations in the U.S.: A prospective cohort study.PloS one · 2025Article
- Association of serum 25-hydroxy-vitamin D concentration and risk of mortality in cancer survivors in the United States.BMC cancer · 2024Article
- Vitamin D Fortification: A Promising Approach to Overcome Drug Resistance and Tolerance in Therapeutic Interventions.Scientifica · 2024Review
- 25-Hydroxycholecalciferol Inhibits Cell Growth and Induces Apoptosis in SiHa Cervical Cells via Autocrine Vitamin D Metabolism.Biomedicines · 2023Article
- Article
- Science-based policy: targeted nutrition for all ages and the role of bioactives.European journal of nutrition · 2021Article
- Genetic Polymorphism of Vitamin D Family GenesFrontiers in genetics · 2021Article
- Consensus statement from 2Reviews in endocrine & metabolic disorders · 2020Article
- Cholecalciferol Inhibits Cell Growth and Induces Apoptosis in the CaSki Cell Line.Medical sciences (Basel, Switzerland) · 2020Article
- Switching to a Healthy Diet Prevents the Detrimental Effects of Western Diet in a Colitis-Associated Colorectal Cancer Model.Nutrients · 2019Article
- Potential Role of Extracellular ATP Released by Bacteria in Bladder Infection and Contractility.mSphere · 2019Article
- Vitamin D supplementation for prevention of cancer: The D2d cancer outcomes (D2dCA) study.Contemporary clinical trials · 2019Article
- Anaplastic large cell lymphoma, with 1,25(OH)Journal of clinical and experimental hematopathology : JCEH · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Vitamin D deficiency and low calcium intake are considered risk factors for several cancers. Vitamin D, synthesized in the skin or ingested through the diet, is transformed through two hydroxylation steps to the active metabolite, 1α,25-dihydroxyvitamin D3 (1,25-D3). 25-hydroxylases in the liver are responsible for the first hydroxylation step. The ultimate activation is performed by the renal 25-hydroxyvitamin D 1α-hydroxylase (CYP27B1), while the 1,25-dihydroxyvitamin D 24-hydroxylase (CYP24A1) in the kidneys degrades the active metabolite. These two renal vitamin D hydroxylases control the endocrine serum 1,25-D3 levels, and are responsible for maintaining mineral homeostasis. In addition, the active vitamin D hormone 1,25-D3 regulates cellular proliferation, differentiation, and apoptosis in multiple tissues in a paracrine/autocrine manner. Interestingly, it is the low serum level of the precursor 25- hydroxyvitamin D3 (25-D3) that predisposes to numerous cancers and other chronic diseases, and not the serum concentration of the active vitamin D hormone. The extra-renal autocrine/paracrine vitamin D system is able to synthesize and degrade locally the active 1,25- D3 necessary to maintain normal cell growth and to counteract mitogenic stimuli. Thus, vitamin D hydroxylases play a prominent role in this process. The present review describes the role of the vitamin D hydroxylases in cancer pathogenesis and the cross-talk between the extra-renal autocrine/paracrine vitamin D system and calcium in cancer prevention.
Indexed as
Identifiers
23094918PMC3826118W2102284674What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.